Michael Asbach,

DMSc, PA-C, Psych-CAQ

Associate Director, Interventional Psychiatry, DENT Neurologic Institute

Michael's Shared Resources

Study Uncovers Neural Network Vulnerability in Tardive Dyskinesia’s Orofacial Symptoms

In a recent study, researchers aimed to understand why tardive dyskinesia (TD) often exhibits orofacial symptoms, while also exploring the neural network involved. The researchers conducted graph analysis on a

TD Frequency and Antipsychotics

Researchers of a study examined the incidence of tardive dyskinesia (TD) between long-acting injectable antipsychotics (LAI-APs) and equivalent oral antipsychotics (O-APs), LAI first-generation antipsychotics and LAI second-generation antipsychotics (LAI-SGAs), as

CURATED BY:
Michael Asbach

Diagnostic and Treatment Basics in TD: A Review

Tardive dyskinesia (TD) involves involuntary movements of the tongue, lips, face, trunk, and extremities, and it can be linked to considerable functional impairment and can be socially stigmatizing. Once a

CURATED BY:
Michael Asbach

Impact of Treatment for a Patient With Tardive Dyskinesia

A video from Genoa Healthcare shows a patient with tardive dyskinesia and the impact it has had on their life before and during treatment.

CURATED BY:
Michael Asbach

Using “Extrapyramidal Symptoms” in Practice: Expert Perspective

In this article, John J. Miller, MD, editor-in-chief of Psychiatric Times™, gives insight on the diversity of movement disorders that may result from the use of dopamine-2 receptor blocking agents. He

CURATED BY:
Michael Asbach

An Overview of Extrapyramidal Side Effects

One of the most common adverse effects from dopamine-receptor blocking agents are drug-induced movement disorders, or extrapyramidal side effects (EPS). The below link walks through the cause, pathophysiology, and presentation

CURATED BY:
Michael Asbach